Health Care [ 11/12 ] | Life Sciences Tools & Services [ 43/75 ]
NASDAQ | Common Stock
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific.
The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell.
The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis.
It serves various academic, government, biopharmaceutical, biotechnology, and other institutions.
The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.32 Increased by +39.62% | -0.48 Increased by +33.33% |
| Apr 30, 24 | -0.50 Decreased by -13.64% | -0.50 |
| Feb 15, 24 | -0.41 Decreased by -173.33% | -0.36 Decreased by -13.89% |
| Nov 2, 23 | -0.79 Decreased by -113.51% | -0.46 Decreased by -71.74% |
| Aug 3, 23 | -0.53 Increased by +7.02% | -0.40 Decreased by -32.50% |
| May 3, 23 | -0.44 Decreased by -15.79% | -0.37 Decreased by -18.92% |
| Feb 15, 23 | -0.15 Increased by +6.25% | -0.31 Increased by +51.61% |
| Nov 2, 22 | -0.37 Decreased by -146.67% | -0.46 Increased by +19.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 153.10 M Increased by +4.28% | -37.90 M Increased by +39.28% | Decreased by -24.75% Increased by +41.77% |
| Mar 31, 24 | 141.01 M Increased by +5.01% | -59.95 M Decreased by -18.13% | Decreased by -42.52% Decreased by -12.50% |
| Dec 31, 23 | 183.98 M Increased by +17.76% | -48.95 M Decreased by -184.36% | Decreased by -26.61% Decreased by -141.47% |
| Sep 30, 23 | 153.64 M Increased by +17.22% | -92.99 M Decreased by -121.85% | Decreased by -60.52% Decreased by -89.26% |
| Jun 30, 23 | 146.82 M Increased by +28.10% | -62.41 M Increased by +3.17% | Decreased by -42.51% Increased by +24.41% |
| Mar 31, 23 | 134.28 M Increased by +17.28% | -50.75 M Decreased by -19.65% | Decreased by -37.79% Decreased by -2.02% |
| Dec 31, 22 | 156.23 M Increased by +8.85% | -17.21 M Increased by +6.69% | Decreased by -11.02% Increased by +14.28% |
| Sep 30, 22 | 131.07 M Increased by +4.61% | -41.91 M Decreased by -144.10% | Decreased by -31.98% Decreased by -133.34% |